TY - JOUR
T1 - The Children's Oncology Group Adolescent and Young Adult Responsible Investigator Network
T2 - A New Model for Addressing Site-Level Factors Impacting Clinical Trial Enrollment
AU - Roth, Michael
AU - Mittal, Nupur
AU - Saha, Aniket
AU - Freyer, David R.
N1 - Funding Information:
This work was supported by the Children’s Oncology Group Chair’s Grant (NIH NCTN Grant: 2U10CA180886) (M.R., D.R.F.) and the Aflac Foundation (D.R.F.).
Funding Information:
This work was supported by the Children's Oncology Group Chair's Grant (NIH NCTN Grant: 2U10CA180886) (M.R., D.R.F.) and the Aflac Foundation (D.R.F.).
Publisher Copyright:
© Copyright 2020, Mary Ann Liebert, Inc.
PY - 2020/8
Y1 - 2020/8
N2 - Purpose: In the Children's Oncology Group (COG), there is precedent for scientific committees designating institutional Responsible Investigators (RIs) to promote clinical trial enrollment and coordinate related research activities. In response to low enrollment of adolescents and young adults (AYAs) on COG clinical trials, the COG AYA RI Network was established. Leveraging this network, we undertook an initiative to identify site-level factors influencing AYA enrollment. Methods: The overarching goal of the AYA RI Network is to increase AYA enrollment onto COG trials. At each site, RIs highlight AYA disparities, facilitate activation of relevant trials, improve recruitment processes, and expand interactions with medical oncologists. Through a series of monthly national webinars and workshops, participating RIs reported local barriers and facilitators enrolling AYAs. A mixed-methods approach was utilized to determine major themes of factors affecting site-level enrollment. Results: For this report, there were 145 participating RIs representing 122 demographically and geographically diverse sites. There were 13 interactive webinars and 3 symposia involving 25 speakers focused on addressing enrollment barriers. Major thematic categories for site-level barriers were (1) Lack of available trials; (2) Poor communication between pediatric and medical oncology; (3) Logistical constraints to accessing trials; and (4) Need for leadership support, sufficient resources and appropriate policies. Conclusion: The COG AYA RI Network has identified multiple site-level barriers impeding AYA clinical trial enrollment and represents a novel model for developing and implementing appropriate solutions through a nationally coordinated strategy.
AB - Purpose: In the Children's Oncology Group (COG), there is precedent for scientific committees designating institutional Responsible Investigators (RIs) to promote clinical trial enrollment and coordinate related research activities. In response to low enrollment of adolescents and young adults (AYAs) on COG clinical trials, the COG AYA RI Network was established. Leveraging this network, we undertook an initiative to identify site-level factors influencing AYA enrollment. Methods: The overarching goal of the AYA RI Network is to increase AYA enrollment onto COG trials. At each site, RIs highlight AYA disparities, facilitate activation of relevant trials, improve recruitment processes, and expand interactions with medical oncologists. Through a series of monthly national webinars and workshops, participating RIs reported local barriers and facilitators enrolling AYAs. A mixed-methods approach was utilized to determine major themes of factors affecting site-level enrollment. Results: For this report, there were 145 participating RIs representing 122 demographically and geographically diverse sites. There were 13 interactive webinars and 3 symposia involving 25 speakers focused on addressing enrollment barriers. Major thematic categories for site-level barriers were (1) Lack of available trials; (2) Poor communication between pediatric and medical oncology; (3) Logistical constraints to accessing trials; and (4) Need for leadership support, sufficient resources and appropriate policies. Conclusion: The COG AYA RI Network has identified multiple site-level barriers impeding AYA clinical trial enrollment and represents a novel model for developing and implementing appropriate solutions through a nationally coordinated strategy.
KW - cancer clinical trial
KW - disparity
KW - enrollment
UR - http://www.scopus.com/inward/record.url?scp=85089301679&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089301679&partnerID=8YFLogxK
U2 - 10.1089/jayao.2019.0139
DO - 10.1089/jayao.2019.0139
M3 - Article
C2 - 32077782
AN - SCOPUS:85089301679
SN - 2156-5333
VL - 9
SP - 522
EP - 527
JO - Journal of adolescent and young adult oncology
JF - Journal of adolescent and young adult oncology
IS - 4
ER -